Diagnostic and prognostic value of telomerase assay in lung cancer

Archives of Medical Science

Volumn 4, Issue 4, 2008, Pages 353-357

  Targowski, Tomasz ^a   Jahnz Rózyk, Karina ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Lung cancer; Non small cell carcinoma; Small cell lung cancer; Telomerase

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; GV 1001; PEPTIDE VACCINE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE REVERSE TRANSCRIPTASE P572Y; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CARCINOMA IN SITU; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; GENE EXPRESSION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEEDLE BIOPSY; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TELOMERE; TRANSTHORACIC BIOPSY;

EID: 60249085077     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Travis WD, Brambilla E, Müller-Hermelink A, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classification of tumours. IARC Press, Lyon 2004; 1-25.
2. Roszkowski K. Lung tumours. In: Respiratory system diseases. Rowińska-Zakrzewska, Kuś (eds). PZWL Warsaw 2003; 563-97.
3. Zatoński W, Tyczyński J. Malignant tumours in Poland in 1995, Cancer Centre. Maria-Sklodowska-Curie Memorial Institute. National Tumours Register. Warsaw 1998.
4. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128: 452-62.
5. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
7. Greider CW, Blackburn EH. Telomery, telomeraza, rak (E. Bartnik) [Polish]. Świat Nauki 1996; 4: 34-9.
8. Nakamura TM, Cech TR. Reversing time: origin of telomerase. Cell 1998; 92: 587-90.
9. Muller HJ. The remarking of chromosomes. The collecting net. Woods Hole 1938; 13: 181-98.
10. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10114-8.
11. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-8.
12. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblast. Nature 1990; 345: 458-60.
13. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
14. Cooper DN. The molecular genetics of lung cancer. Springer, Berlin 2005.
15. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995; 87: 895-902.
16. Shammas MA, Koley H, Beer DG, Li C, Goyal RK, Munschi NC. Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology 2004; 126: 1337-46.
17. Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004; 22: 1807-14.
18. Counter CM, Hirte HW, Baccheetti S, Harley CB. Telomerase acitvity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994; 91: 2900-4.
19. Hirashima T, Yoshitaka O, Nitta T, et al. Telomerase activity in endoscopically visible lung cancer. Anticancer Res 2001; 21: 3685-9.
20. Langford LA, Piatyszek MA, Xu R, Schold SC Jr, Shay JW. Telomerase activity in human brain tumors. Lancet 1995; 346: 1267-8.
21. Lee JC, Jong HS, Yoo CG, Han SK, Shim YS, Kim YW. Telomerase activity in lung cancer cell lines and tissues. Lung Cancer 1998; 21: 99-103.
22. Tahara H, Nakanishi T, Kitamoto M, et al. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995; 55: 2734-6.
23. Rathi A, Kazuo Y, Onuki N, Virmani A, Gazdar AF. Telomerase and lung cancer. In: Lung tumors. Fundamental Biology and Clinical Management. Brambilla, Brambilla (ed.). Marcel Dekker, Inc. New York, USA 1999; 269-78.
24. Kawai T, Hiroi S, Nakanishi K, Meeker AK. Telomere length and telomerase expression in atypical adenomatous hyperplasia and small bronchioalveolar carcinoma of the lung. Am J Clin Pathol 2007; 127: 254-62.
25. Hiyama E, Saeki T, Hiyama K, et al. Telomerase activity as a marker of breast carcinoma in fine-needle aspirated samples. Cancer 2000; 90: 235-8.
26. Jin S, Zhang W, Teng M, et al. Significance of telomerase activity detection by fine-needle aspiration in patients with breast cancer [Chinese]. Zhonghua Bing Li Xue Za Zhi 1999; 28: 334-6.
27. Mu XC, Brien TP, Ross JS, Lowry CV, McKenna BJ. Telomerase activity in benign and malignant cytologic fluids. Cancer 1999; 87: 93-9.
28. Xinarianos G, Scott FM, Liloglou T, et al. Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung disease. Lung Cancer 2000; 28: 37-42.
29. Taillade L, Penault-Llorca F, Boulet T, et al. Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007; 18: 1043-50.
30. Pasrija T, Srinivasan R, Behera D, Majumdar S. Telomerase activity in sputum and telomerase and its components in biopsies of advanced lung cancer. Eur J Cancer 2007; 43: 1476-82.
31. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226: 756-61.
32. Targowski T, Jahnz-Rozyk K, Szkoda T, From S, Qandil N, Płusa T. Telomerase activity in transthoracic fine-needle biopsy aspirates as a marker of peripheral lung cancer. Thorax 2008; 63: 342-4.
33. Taga S, Osaki T, Ohgami A, Imoto H, Yasumoto K. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg 1999; 230: 715-20.
34. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, Sugarbaker DJ. Molecular and pathologic markers in stage I non-small cell carcinoma of the lung. J Clin Oncol 1995; 13: 1265-79.
35. Fujita Y, Fujikane T, Fujiuchi S, et al. The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 2003; 98: 1008-13.
36. Targowski T. Jahnz-Rózyk K, Szkoda T, Płusa T, From S. Telomerase activity in transthoracic fine-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients' survival. Lung Cancer 2008; 61: 97-103.
37. Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L, Lianidou ES. Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer. Clin Chem 2007; 53: 53-61.
38. Stanley K, Stjernsward J. Lung cancer in developed and developing countries. In: Basic and clinical concepts of lung cancer. Hansen HH. (ed.). Kluwer, Dordrecht 1989; 1-14.
39. Lantuéjoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 2007; 120: 1835-41.
40. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005; 65: 7866-73.
41. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006; 55: 1553-64.
42. Bolonaki I, Kotsakis A, Papadimitraki E, et al. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. J Clin Oncol 2007; 25: 2727-34.
43. Zaffaroni N, De Polo D, Villa R, et al. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. J Pathol 2003; 201: 127-33.
44. Sarvesvaran J, Going JJ, Milroy R, Kaye SB, Keith WN. Is small cell lung cancer the perfect target for anti-telomerase treatment. Carcinogenesis 1999; 20: 1649-51.